CMV disease · solid organ transplant recipients
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Valaciclovir showed no clear difference in leucopenia compared with ganciclovir or valganciclovir (moderate certainty).
1 finding from 1 review
SCr at the end of · solid organ transplant recipients
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (long‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of HSL during use of the preventative intervention (by culture) · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Viral load (shedding) in saliva · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in viral load (shedding) in saliva compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
It is very uncertain whether valaciclovir (suppressive regimen changes adverse effects during use of the preventative intervention compared with episodic regimen) (very low certainty).
1 finding from 1 review
Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Severity (pain) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Severity of attack of recurrent herpes labialis during use of the preventative intervention (maximum lesion area) · participants with recurrent herpes labialis
1 finding from 1 review